To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
BASF relocates production of Kolliphor TPGS to its Minden site
03-05-2012: BASF will transfer the pharmaceutical production of KolliphorTM TPGS (Speziol®TPGS Pharma, vitamin E polyethylene glycol succinate), manufactured at the company’s Kankakee, Illinois (USA), site, to its Minden, Germany, facility. The transition is expected to be completed by the first quarter of 2014.
“Expanding the Kolliphor TPGS manufacturing capacity at our Minden site is another example of BASF’s commitment to the pharmaceutical and dietary supplement market. The relocation creates a more centralized production facility, reduces complexity in the production setup, and provides room for future expansion,” said Dr. Thorsten Schmeller, Head of Global Marketing New Products at BASF’s Global Business Unit Pharma Ingredients & Services. The Minden site has manufactured active pharmaceutical ingredients (APIs) and excipients under cGMP for more than 70 years and is regularly inspected by the FDA and European health authorities. Schmeller: “Thanks to the ICH Q7 quality management standards at our Minden site, we will be able to offer a Kolliphor TPGS grade that fulfills the requirements of an API.”
Until the production in Minden is fully operational, BASF will continue to manufacture Kolliphor TPGS at the Kankakee site, which will fully support pharmaceutical and nutraceutical customers during the transition. “We have scheduled a generous supply overlap that we expect allows for a seamless transition,” added Schmeller. “Our projection also takes into account the appropriate qualification period required to transition products used in pharmaceutical applications . ” Kolliphor TPGS production at the Minden site is expected to start in the first quarter of 2013.
The Kankakee site remains an important production facility for BASF’s nutrition and health business. Besides food ingredients, the company manufactures ingredients for soaps, shampoos, detergents, coatings, inks and adhesives at the site.
Contact / Request information
Request further information free of charge:
This is where you can add this news to your personal favourites
- 1Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 2Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 3Vivacta Initiates Development of Point of Care Test for Vitamin D
- 4Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 5A light switch inside the brain
- 6Researchers divide enzyme to conquer genetic puzzle
- 7New study confirms fungal infection of the foot is a risk factor for bacterial tissue infection of the leg
- 8Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 9Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 10Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
- Frost & Sullivan commends Merck Serono for its excellence in product differe ...
- Analytik Jena AG establishes subsidiary in Thailand
- Eurofins MWG Operon launches SmartSeq
- Bone Therapeutics Invests in Cell Therapy Manufacturing Facility
- SCHOTT strengthens its position in the Asian pharmaceutical market
- Going live – immune cell activation in multiple sclerosis
- DNA damage: The dark side of respiration
- EMBO announces new members for 2013
- Evotec and Harvard University to collaborate on development of new class of antibacterials
- Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013